Skip to main content
诺思兰德 logo

诺思兰德 — Investor Relations & Filings

Ticker · 920047 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 539 across all filing types
Latest filing 2024-05-19 Investor Presentation
Country CN China
Listing Beijing Stock Exchange 920047

About 诺思兰德

https://www.northland-bio.com/

Northland Biotech focuses on the research, development, and commercialization of gene therapies and recombinant protein pharmaceuticals. The company’s primary therapeutic areas include cardiovascular diseases, peripheral arterial diseases, and ophthalmology. Its core R&D pipeline features NL003, a hepatocyte growth factor gene therapy targeting critical limb ischemia, and NL005, a recombinant human thymosin beta 4 for treating myocardial ischemia. Beyond its innovative pipeline, the company maintains advanced manufacturing facilities for biologics and ophthalmic preparations, producing a range of specialized eye drops. By leveraging its proprietary technology platforms, Northland Biotech aims to provide effective treatments for chronic and degenerative conditions through advanced molecular medicine.

Recent filings

Filing Released Lang Actions
投资者关系活动记录表
Investor Presentation Classification · 95% confidence The document is an investor relations activity record for a 2023 annual report earnings presentation held on May 17, 2024. It includes detailed Q&A about the company's 2023 performance and future plans, but it is not the actual annual report itself. The document length is 3240 characters, which is relatively short and consistent with a meeting or event summary rather than a full financial report. It references the 2023 annual report and provides a link to related materials, indicating this is a summary or record of the earnings presentation rather than the report itself. Therefore, this document fits best as an Investor Presentation (IP) rather than an Annual Report (10-K) or Earnings Release (ER).
2024-05-19 Chinese
2023年年度报告业绩说明会预告公告
AGM Information Classification · 95% confidence The document is a notice announcing a scheduled annual report earnings explanation meeting (业绩说明会) for the 2023 annual report. It references the actual 2023 annual report and its summary, which were previously published and provides details about the meeting time, location, participants, and how investors can participate and submit questions. The document itself does not contain the annual report or financial data but is an announcement related to the annual report. The document length is short (1074 characters), and it clearly states the report was disclosed earlier with specific announcement numbers. Therefore, this is a Report Publication Announcement or related meeting notice, best classified as AGM Information (AGM-R) since it is about an annual report explanation meeting, which is a type of AGM-related presentation material.
2024-05-13 Chinese
中泰证券股份有限公司关于北京诺思兰德生物技术股份有限公司向不特定合格投资者公开发行股票之保荐工作总结报告书
Capital/Financing Update Classification · 95% confidence The document is a detailed report from Zhongtai Securities Co., Ltd. acting as the sponsor for Beijing Northland Biotech Co., Ltd. regarding the public offering of shares to qualified investors and listing on the Beijing Stock Exchange. It includes comprehensive descriptions of the sponsorship work, due diligence, ongoing supervision, major events during the sponsorship period, changes in use of raised funds, and compliance with regulatory requirements. The document references regulatory frameworks and supervisory duties, and it is a summary report of the sponsorship work rather than a financial report or announcement. It is not an annual or interim financial report, earnings release, or a simple announcement. The document length is 4459 characters, which is substantial and contains substantive content. This type of document fits best under the category of Capital/Financing Update (CAP) because it relates to the public issuance of shares and the associated sponsorship and regulatory compliance work. It is not a report publication announcement or regulatory filing as it contains detailed substantive content rather than just a notice or certification.
2024-05-06 Chinese
2024年一季度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled "北京诺思兰德生物技术股份有限公司 2024 年第一季度报告" which translates to "Beijing Northland Biotechnology Co., Ltd. 2024 First Quarter Report." It contains detailed financial statements including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and notes on financial data for the period ending March 31, 2024. The document explicitly states it is a quarterly report (第一季度报告) and includes comprehensive financial data and analysis for the quarter. It is unaudited but contains substantive financial information for the interim period. This matches the definition of an Interim / Quarterly Report (IR). The document length is about 15,000 characters, indicating it is the full report, not just an announcement or certification. Therefore, the correct classification is IR with high confidence. Q1 2024
2024-04-24 Chinese
关于选举第六届董事会薪酬与考核委员会委员的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the election of members to the company's sixth board remuneration and assessment committee. It references compliance with company law, governance rules, and board meeting resolutions. There is no financial data, earnings information, or report content. The document concerns board/management information, specifically about changes or appointments within the board committees. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused on governance changes, not a full report or announcement of a report publication.
2024-04-24 Chinese
2023年度股东大会通知公告
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2023 Annual General Meeting (AGM) of Beijing Northland Biotech Co., Ltd. It includes information about the meeting date, voting methods (including online voting), agenda items to be discussed and approved at the AGM, such as the 2023 board work report, supervisory board report, independent directors' reports, audit firm appointment, financial reports, equity incentive plans, amendments to the articles of association, and other corporate governance matters. The document is not the actual annual report or financial statements but a formal announcement and invitation to shareholders to attend and vote at the AGM. It also references where detailed reports can be found but does not contain the reports themselves. The document length is about 6980 characters, which is consistent with a detailed AGM notice. Therefore, the filing type is AGM Information (AGM-R).
2024-04-24 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.